Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

4/9/2025

Janusmed kön och genus

Janusmed kön och genus – Fragmin (med konserveringsmedel)

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Dalteparin Testmiljö

Dalteparin

Klass : C

Visa all info

Skriv ut

Kontakta oss

Produkter

Fragmin, Fragmin (med konserveringsmedel)

Fragmin, Fragmin (med konserveringsmedel)
ATC-koder

B01AB04

B01AB04
Substanser

dalteparin, dalteparinnatrium

dalteparin, dalteparinnatrium
Sammanfattning

Dalteparin har visats förebygga venös tromboembolism likvärdigt hos kvinnor och män.  Vid akut hjärtinfarkt fann man i en placebokontrollerad studie att kvinnor hade större nytta av dalteparin som koagulationshämmande behandling. Dalteparin givet i samma dos till patienter med instabil koronarsjukdom gav fler blödningar hos kvinnor än hos män. Kvinnorna fick också en högre aktivitet av antifaktor-Xa, det vill säga hade en högre antikoagulationseffekt än män.

Dalteparin har visats förebygga venös tromboembolism likvärdigt hos kvinnor och män.  Vid akut hjärtinfarkt fann man i en placebokontrollerad studie att kvinnor hade större nytta av dalteparin som koagulationshämmande behandling. Dalteparin givet i samma dos till patienter med instabil koronarsjukdom gav fler blödningar hos kvinnor än hos män. Kvinnorna fick också en högre aktivitet av antifaktor-Xa, det vill säga hade en högre antikoagulationseffekt än män.
Background

Pharmacokinetics and dosing
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of dalteparin have been found. Dalteparin is dosed per kilogram body weight and the dosage regimen is thus individual. The maintenance dosage for unstable coronary artery disease is different in men and women depending on the body weight; the dose 5000 IE two times daily is recommended for women <80 kg and men <70 kg, and the dose 7500 IE two times daily is recommended for women >80 kg and men >70 kg [1].

Effects
Unstable coronary artery disease
Subgroup results from the FRISC II trial (1708 men, 749 women) [2] indicated that men with unstable coronary artery disease and treatment with early invasive revascularization and medical pretreatment with dalteparin sodium plus antianginal medications reduced their risk of death or recurrent myocardial infarction after 3 months more than women [3]. After 6 months, there was no sex difference in risk [2]. However, due to the relatively low frequence of women, this finding needs to be confirmed. Follow-up after 15 ye......

Visa hela bakgrundstexten

# Pharmacokinetics and dosing No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of dalteparin have been found. Dalteparin is dosed per kilogram body weight and the dosage regimen is thus individual. The maintenance dosage for unstable coronary artery disease is different in men and women depending on the body weight; the dose 5000 IE two times daily is recommended for women <80 kg and men <70 kg, and the dose 7500 IE two times daily is recommended for women >80 kg and men >70 kg [1]. # Effects **Unstable coronary artery disease** Subgroup results from the FRISC II trial (1708 men, 749 women) [2] indicated that men with unstable coronary artery disease and treatment with early invasive revascularization and medical pretreatment with dalteparin sodium plus antianginal medications reduced their risk of death or recurrent myocardial infarction after 3 months more than women [3]. After 6 months, there was no sex difference in risk [2]. However, due to the relatively low frequence of women, this finding needs to be confirmed. Follow-up after 15 years showed that early invasive treatment had a beneficial effect on the composite end point death or myocardial infarction in men, but no effects in women. However, there was no sex difference in the composite end point death or readmission to hospital for ischemic heart disease  [4]. **Prevention of venous thromboembolism** A randomized, placebo-controlled, double-blind study (PREVENT), examined dalteparin for prevention of venous thromboembolic events in medically ill patients (1772 men, 1909 women). Dalteparin 5000 IU once daily for two weeks reduced the incidence of the primary endpoint (risk of symptomatic DVT, asymptomatic proximal DVT, non-fatal or fatal PE and/or sudden death) similarly in men and women [5, 6]. Dalteparin as secondary prevention of VTE among cancer patients was investigated in the CLOT trial (328 men, 348 women), a randomized open-label study. Subgroup analyses showed no sex differences in the efficacy of dalteparin compared to an oral anticoagulant (warfarin or acenocoumarol) [7]. **Myocardial infarction** The FRAMI trial (569 men, 207 women), a randomized double-blind placebo-controlled study, reported that dalteparin 150 IU/kg reduced left ventricular thrombus formation in acute anterior myocardial infarction and female sex was associated with a lower risk of developing left ventricular thrombus (OR 0.50, 95%CI 0.26-0.94) [8]. # Adverse effects In the first FRISC trial (464 men, 273 women), dalteparin was given in the same dose to men and women with unstable coronary artery disease. Women had an increased frequency of minor bleedings during the acute phase treatment (5-8 days, 120 IU/kg twice daily) as well as during home treatment period (35-45 days, self-administration 7500 IU/kg once daily). Relative risk ratio women/men was 2.88 during acute phase and 2.36 during home treatment. The bleeding was mainly ecchymoses at the injection site. Women had a higher antifactor Xa activity during the home treatment phase. In spite of that, multiple regression analyses showed that female sex was associated with high antifactor Xa levels during the acute phase as well as a significant association at the end of the home treatment. The relationship between anti-Xa activity and patient’s sex was significant even after adjusting for age, body weight and smoking. Since the distribution of volume of LMWH (Low molecular weight heparins) seems to be equivalent to the plasma compartment, blood volume might be one factor having  influence on the sex- differences in anti-Xa activity [9]. In the PREVENT trial mentioned above, more women had major bleeds while more men had minor bleeds. However, there were no sex difference in the overall incidence of bleeding [5]. No sex-divided data of safety outcomes were reported in other pivotal studies (FRAMI, CLOT) [7, 8]. # Reproductive health issues The half-time of dalteparin is around 4-5 h during the last trimester in pregnant women compared to 2-4 hours in non-pregnant women which needs to be considered when estimating remaining anticoagulant effect [1]. Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Försäljning på recept

Visa hela försäljning på recept

Fler kvinnor än män hämtade ut injektionsvätska innehållande dalteparin (ATC-kod B01AB04) på recept i Sverige år 2018, totalt 39 819 kvinnor och 27 355 män. Det motsvarar 7,9 respektive 5,4 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 70 år och äldre hos båda könen. I åldersgruppen yngre än 60 år var injektionsvätska innehållande dalteparin i genomsnitt 2,4 gånger vanligare hos kvinnor medan i åldersgruppen 60 år och äldre var det i genomsnitt 1,1 gånger vanligare hos män [10].
Referenser

Visa referenser

  1. Fragmin (dalteparin). Summary of Product Characteristics. Swedish Medical Products Agency; 2016 [cited 2019-01-24].

  2. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354(9180):708-15.

  3. Husted SE. Targeting treatment for optimal outcome. Clin Cardiol. 2000;23 Suppl 1:I18-22.

  4. Wallentin L, Lindhagen L, Ärnström E, Husted S, Janzon M, Johnsen SP et al. Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study. Lancet. 2016;388(10054):1903-1911.

  5. Food and Drug Administration (FDA). Medical review - FRAGMIN (dalteparin sodium). Drugs@FDA [www]. [updated 2013-12-10, cited 2019-01-24].

  6. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110(7):874-9.

  7. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-53.

  8. Kontny F, Dale J, Abildgaard U, Pedersen TR. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol. 1997;30(4):962-9.

  9. Toss H, Wallentin L, Siegbahn A. Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease. Am Heart J. 1999;137:72-8.

  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2019-01-30.]

  1. Fragmin (dalteparin). Summary of Product Characteristics. Swedish Medical Products Agency; 2016 [cited 2019-01-24].
  2. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354(9180):708-15.
  3. Husted SE. Targeting treatment for optimal outcome. Clin Cardiol. 2000;23 Suppl 1:I18-22.
  4. Wallentin L, Lindhagen L, Ärnström E, Husted S, Janzon M, Johnsen SP et al. Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study. Lancet. 2016;388(10054):1903-1911.
  5. Food and Drug Administration (FDA). Medical review - FRAGMIN (dalteparin sodium). Drugs@FDA [www]. [updated 2013-12-10, cited 2019-01-24].
  6. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110(7):874-9.
  7. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-53.
  8. Kontny F, Dale J, Abildgaard U, Pedersen TR. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol. 1997;30(4):962-9.
  9. Toss H, Wallentin L, Siegbahn A. Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease. Am Heart J. 1999;137:72-8.
  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2019-01-30.]
Uppdaterat

Litteratursökningsdatum: 1/24/2019

Litteratursökningsdatum: 1/24/2019
Fasstexter

Visa fasstexter

C C
C C

Dalteparin Testmiljö

Dalteparin

Klass : C

Visa all info

Skriv ut

Kontakta oss

Produkter

Fragmin, Fragmin (med konserveringsmedel)

Fragmin, Fragmin (med konserveringsmedel)
ATC-koder

B01AB04

B01AB04
Substanser

dalteparin, dalteparinnatrium

dalteparin, dalteparinnatrium
Sammanfattning

Dalteparin har visats förebygga venös tromboembolism likvärdigt hos kvinnor och män.  Vid akut hjärtinfarkt fann man i en placebokontrollerad studie att kvinnor hade större nytta av dalteparin som koagulationshämmande behandling. Dalteparin givet i samma dos till patienter med instabil koronarsjukdom gav fler blödningar hos kvinnor än hos män. Kvinnorna fick också en högre aktivitet av antifaktor-Xa, det vill säga hade en högre antikoagulationseffekt än män.

Dalteparin har visats förebygga venös tromboembolism likvärdigt hos kvinnor och män.  Vid akut hjärtinfarkt fann man i en placebokontrollerad studie att kvinnor hade större nytta av dalteparin som koagulationshämmande behandling. Dalteparin givet i samma dos till patienter med instabil koronarsjukdom gav fler blödningar hos kvinnor än hos män. Kvinnorna fick också en högre aktivitet av antifaktor-Xa, det vill säga hade en högre antikoagulationseffekt än män.
Background

Pharmacokinetics and dosing
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of dalteparin have been found. Dalteparin is dosed per kilogram body weight and the dosage regimen is thus individual. The maintenance dosage for unstable coronary artery disease is different in men and women depending on the body weight; the dose 5000 IE two times daily is recommended for women <80 kg and men <70 kg, and the dose 7500 IE two times daily is recommended for women >80 kg and men >70 kg [1].

Effects
Unstable coronary artery disease
Subgroup results from the FRISC II trial (1708 men, 749 women) [2] indicated that men with unstable coronary artery disease and treatment with early invasive revascularization and medical pretreatment with dalteparin sodium plus antianginal medications reduced their risk of death or recurrent myocardial infarction after 3 months more than women [3]. After 6 months, there was no sex difference in risk [2]. However, due to the relatively low frequence of women, this finding needs to be confirmed. Follow-up after 15 ye......

Visa hela bakgrundstexten

# Pharmacokinetics and dosing No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of dalteparin have been found. Dalteparin is dosed per kilogram body weight and the dosage regimen is thus individual. The maintenance dosage for unstable coronary artery disease is different in men and women depending on the body weight; the dose 5000 IE two times daily is recommended for women <80 kg and men <70 kg, and the dose 7500 IE two times daily is recommended for women >80 kg and men >70 kg [1]. # Effects **Unstable coronary artery disease** Subgroup results from the FRISC II trial (1708 men, 749 women) [2] indicated that men with unstable coronary artery disease and treatment with early invasive revascularization and medical pretreatment with dalteparin sodium plus antianginal medications reduced their risk of death or recurrent myocardial infarction after 3 months more than women [3]. After 6 months, there was no sex difference in risk [2]. However, due to the relatively low frequence of women, this finding needs to be confirmed. Follow-up after 15 years showed that early invasive treatment had a beneficial effect on the composite end point death or myocardial infarction in men, but no effects in women. However, there was no sex difference in the composite end point death or readmission to hospital for ischemic heart disease  [4]. **Prevention of venous thromboembolism** A randomized, placebo-controlled, double-blind study (PREVENT), examined dalteparin for prevention of venous thromboembolic events in medically ill patients (1772 men, 1909 women). Dalteparin 5000 IU once daily for two weeks reduced the incidence of the primary endpoint (risk of symptomatic DVT, asymptomatic proximal DVT, non-fatal or fatal PE and/or sudden death) similarly in men and women [5, 6]. Dalteparin as secondary prevention of VTE among cancer patients was investigated in the CLOT trial (328 men, 348 women), a randomized open-label study. Subgroup analyses showed no sex differences in the efficacy of dalteparin compared to an oral anticoagulant (warfarin or acenocoumarol) [7]. **Myocardial infarction** The FRAMI trial (569 men, 207 women), a randomized double-blind placebo-controlled study, reported that dalteparin 150 IU/kg reduced left ventricular thrombus formation in acute anterior myocardial infarction and female sex was associated with a lower risk of developing left ventricular thrombus (OR 0.50, 95%CI 0.26-0.94) [8]. # Adverse effects In the first FRISC trial (464 men, 273 women), dalteparin was given in the same dose to men and women with unstable coronary artery disease. Women had an increased frequency of minor bleedings during the acute phase treatment (5-8 days, 120 IU/kg twice daily) as well as during home treatment period (35-45 days, self-administration 7500 IU/kg once daily). Relative risk ratio women/men was 2.88 during acute phase and 2.36 during home treatment. The bleeding was mainly ecchymoses at the injection site. Women had a higher antifactor Xa activity during the home treatment phase. In spite of that, multiple regression analyses showed that female sex was associated with high antifactor Xa levels during the acute phase as well as a significant association at the end of the home treatment. The relationship between anti-Xa activity and patient’s sex was significant even after adjusting for age, body weight and smoking. Since the distribution of volume of LMWH (Low molecular weight heparins) seems to be equivalent to the plasma compartment, blood volume might be one factor having  influence on the sex- differences in anti-Xa activity [9]. In the PREVENT trial mentioned above, more women had major bleeds while more men had minor bleeds. However, there were no sex difference in the overall incidence of bleeding [5]. No sex-divided data of safety outcomes were reported in other pivotal studies (FRAMI, CLOT) [7, 8]. # Reproductive health issues The half-time of dalteparin is around 4-5 h during the last trimester in pregnant women compared to 2-4 hours in non-pregnant women which needs to be considered when estimating remaining anticoagulant effect [1]. Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Försäljning på recept

Visa hela försäljning på recept

Fler kvinnor än män hämtade ut injektionsvätska innehållande dalteparin (ATC-kod B01AB04) på recept i Sverige år 2018, totalt 39 819 kvinnor och 27 355 män. Det motsvarar 7,9 respektive 5,4 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 70 år och äldre hos båda könen. I åldersgruppen yngre än 60 år var injektionsvätska innehållande dalteparin i genomsnitt 2,4 gånger vanligare hos kvinnor medan i åldersgruppen 60 år och äldre var det i genomsnitt 1,1 gånger vanligare hos män [10].
Referenser

Visa referenser

  1. Fragmin (dalteparin). Summary of Product Characteristics. Swedish Medical Products Agency; 2016 [cited 2019-01-24].

  2. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354(9180):708-15.

  3. Husted SE. Targeting treatment for optimal outcome. Clin Cardiol. 2000;23 Suppl 1:I18-22.

  4. Wallentin L, Lindhagen L, Ärnström E, Husted S, Janzon M, Johnsen SP et al. Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study. Lancet. 2016;388(10054):1903-1911.

  5. Food and Drug Administration (FDA). Medical review - FRAGMIN (dalteparin sodium). Drugs@FDA [www]. [updated 2013-12-10, cited 2019-01-24].

  6. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110(7):874-9.

  7. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-53.

  8. Kontny F, Dale J, Abildgaard U, Pedersen TR. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol. 1997;30(4):962-9.

  9. Toss H, Wallentin L, Siegbahn A. Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease. Am Heart J. 1999;137:72-8.

  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2019-01-30.]

  1. Fragmin (dalteparin). Summary of Product Characteristics. Swedish Medical Products Agency; 2016 [cited 2019-01-24].
  2. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354(9180):708-15.
  3. Husted SE. Targeting treatment for optimal outcome. Clin Cardiol. 2000;23 Suppl 1:I18-22.
  4. Wallentin L, Lindhagen L, Ärnström E, Husted S, Janzon M, Johnsen SP et al. Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study. Lancet. 2016;388(10054):1903-1911.
  5. Food and Drug Administration (FDA). Medical review - FRAGMIN (dalteparin sodium). Drugs@FDA [www]. [updated 2013-12-10, cited 2019-01-24].
  6. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110(7):874-9.
  7. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-53.
  8. Kontny F, Dale J, Abildgaard U, Pedersen TR. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol. 1997;30(4):962-9.
  9. Toss H, Wallentin L, Siegbahn A. Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease. Am Heart J. 1999;137:72-8.
  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2019-01-30.]
Uppdaterat

Litteratursökningsdatum: 1/24/2019

Litteratursökningsdatum: 1/24/2019
Fasstexter

Visa fasstexter